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Abstract
Background: Specific properties of amphiphilic copolymeric micelles like small size, stability, biodegradability and
prolonged biodistribution have projected them as promising vectors for drug delivery. To evaluate the potential of
δ-valerolactone based micelles as carriers for drug delivery, a novel triblock amphiphilic copolymer poly(δ-
valerolactone)/poly(ethylene glycol)/poly(δ-valerolactone) (VEV) was synthesized and characterized using IR, NMR,
GPC, DTA and TGA. To evaluate VEV as a carrier for drug delivery, doxorubicin (DOX) entrapped VEV micelles
(VEVDMs) were prepared and analyzed for in vitro antitumor activity.
Results: VEV copolymer was successfully synthesized by ring opening polymerization and the stable core shell
structure of VEV micelles with a low critical micelle concentration was confirmed by proton NMR and fluorescence
based method. Doxorubicin entrapped micelles (VEVDMs) prepared using a modified single emulsion method were
obtained with a mean diameter of 90 nm and high encapsulation efficiency showing a pH dependent sustained
doxorubicin release. Biological evaluation in breast adenocarcinoma (MCF7) and glioblastoma (U87MG) cells by
flow cytometry showed 2-3 folds increase in cellular uptake of VEVDMs than free DOX. Block copolymer micelles
without DOX were non cytotoxic in both the cell lines. As evaluated by the IC50 values VEVDMs induced 77.8, 71.2,
81.2% more cytotoxicity in MCF7 cells and 40.8, 72.6, 76% more cytotoxicity in U87MG cells than pristine DOX after
24, 48, 72 h treatment, respectively. Moreover, VEVDMs induced enhanced apoptosis than free DOX as indicated by
higher shift in Annexin V-FITC fluorescence and better intensity of cleaved PARP. Even though, further studies are
required to prove the efficacy of this formulation in vivo the comparable G2/M phase arrest induced by VEVDMs at
half the concentration of free DOX confirmed the better antitumor efficacy of VEVDMs in vitro.
Conclusions: Our studies clearly indicate that VEVDMs possess great therapeutic potential for long-term tumor
suppression. Furthermore, our results launch VEV as a promising nanocarrier for an effective controlled drug
delivery in cancer chemotherapy.
Background
In spite of the current advances in cancer, chemotherapy
still faces the major problem of lack of selectivity of antic-
ancer drugs towards neoplastic cells [1]. The efficacy of
chemotherapy is decided by maximum tumor cell killing
effect during the tumor growth phase and minimum expo-
sure of healthy cells to the cytotoxic agent. Continuous
and steady infusion of the drug into the tumor interstitium
is also desirable to exterminate the proliferating cells, to
finally cause tumor regression. Advances in nanotechnol-
ogy have resulted in the evolution of a variety of nano-
sized carriers for controlled and targeted delivery of
chemotherapeutics [2-4]. Moreover, recent advances in
polymer based micelles have opened new frontiers for
drug delivery [5,6] and tumor targeting [7].
Amphiphilic block copolymers have the tendency to
self-assemble into micelles in a selective solvent because of
the presence of both, hydrophilic as well as hydrophobic
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any medium, provided the original work is properly cited.segments [8,9]. These polymeric micelles consist of a core
and shell like structure, in which the inner core is the
hydrophobic part and can be utilized for encapsulation of
drugs, whereas the hydrophilic block constituting the
outer shell provides stabilization. The potential of poly-
meric micelles as drug carriers lie in their unique proper-
ties like small size, prolonged circulation, biodegradability
and thermodynamic stability [10,11]. Moreover, these
micelles have the ability to preferentially target tumor tis-
sues by enhanced permeability and retention effect due to
the small size of the carrier molecule which facilitates the
entry within biological constraints proving their superior-
ity over other particulate carriers [12,13]. Another impor-
tant characteristic of these micelles is the presence of
water compatible polymers like polyethylene glycol (PEG)
which improves the bioavailability of these drug delivery
systems [14,15]. PEG not only saturates these polymeric
particles with water by making them soluble, but also pre-
vents opsonization of these nanocarriers by providing
steric stabilization against undesirable aggregation and
non-specific electrostatic interactions with the surround-
ings [16,17]. This has resulted in an extensive study of
drug formulations using copolymeric micelles with
enhanced antitumor efficacy [18-20]. Although, a number
of polyester based copolymers like caprolactone, valerolac-
tone and lactides have been studied [21-23], serious inves-
tigations on δ-valerolactone based copolymeric micelles
for drug delivery applications are scarcely reported in lit-
erature. For example, doxorubicin based copolymeric
micelles have been investigated [24,25], but the potential
of δ-valerolactone and PEG based micelles as carriers for
controlled delivery is yet to be explored. Doxorubicin
(DOX), an anthracycline antibiotic, is a drug used in the
treatment of a large spectrum of cancers especially breast,
ovarian, brain and lung cancers [26]. However, its thera-
peutic potential is limited due to its short half life [27] and
severe toxicity to healthy tissues resulting in myelosup-
pression and cardiac failure [28,29].
Hence, the aim of this work was to use a δ-valerolac-
tone based amphiphilic block copolymer to develop a
novel micellar controlled delivery system for DOX and
analysis of its anticancer activity. The present study
involves the synthesis of a triblock copolymer of δ-
valerolactone, poly δ-valerolactone)/poly(ethylene gly-
col)/poly(δ-valerolactone) (VEV) by ring opening poly-
merization and characterization using IR, NMR and
GPC. The thermal stability of VEV was analyzed using
DTA and TGA. Micellization followed by biocompatibil-
ity studies of the copolymer were done to evaluate its
potential as a carrier for drug delivery. DOX entrapped
VEV micelles (VEVDMs) were prepared and character-
ized using TEM and the in vitro release kinetics at two
different pH. Their biological evaluation was done in two
different cancer cell lines, breast adenocarcinoma
(MCF7) and glioblastoma (U87MG). Cellular uptake of
micelles was observed and compared to free DOX using
confocal microscopy and FACS. Furthermore, the anti-
proliferative activity was analyzed by MTT assay,
Annexin V-FITC staining and western blot analysis fol-
lowed by alterations in cell division cycle.
Results
Synthesis and characterization of triblock copolymer
The synthetic pathway for the synthesis of VEV is
shown in Figure 1. Ring opening polymerization techni-
que using stannous octoate was implemented to synthe-
size triblock amphiphilic copolymer of δ-valerolactone
using PEG2000.
The chemical structure of obtained VEV copolymer was
confirmed using FT-IR and
1H NMR. In the FT-IR spectra
of the copolymer, the characteristic bands at 2875 cm
-1
and 1100 cm
-1 represent the C-H stretching and C-O-C
band of PEG, respectively. The band at 1726 cm
-1 attribu-
ted the carbonyl (-C = O) stretching of the δ-valerolactone
monomer, respectively (Figure 2).
The
1H NMR spectra acquired in deuterated chloro-
form, which is a good solvent for both blocks, contained
signals from the protons of PEG as well as PVL. The
chemical shifts at ~3.6 ppm (4H, Ha) indicated the -CH2
protons of PEG whereas the characteristic chemical
shifts of δ-valerolactone were seen at 2.4 ppm (2H, Hb),
1.6 ppm (4H, Hc) and 4 ppm (2H, Hd)a ss h o w ni n
Figure 3, confirming the successful synthesis of VEV
copolymer [30].
The molecular weights and single peak with a narrow
molecular weight distribution in the GPC chromatogram
Figure 1 Scheme of polymer synthesis. Synthetic schematic diagram of synthesis of Poly(δ-valerolactone)/Poly(ethylene glycol)/Poly
(δ-valerolactone) (VEV) copolymer using δ-valerolactone and poly(ethylene glycol) as monomers by ring opening polymerization using stannous
octoate as a catalyst is represented.
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ciency of polymerization (Figure 4).
Furthermore, thermal analysis of VEV showed a melt-
ing point near 65.01°C (Figure 5A) which is higher than
that of the individual monomers and thermodynamic
stability up to a temperature of 211.9°C indicating the
increase in stability on polymerization (Figure 5B).
Micellization and characterization
Since VEV is an amphiphilic copolymer, it is expected
to form a core-shell type micelle structure in aqueous
media. NMR analysis showed protons of both VL and
PEG on using CDCl3 as a solvent. However, with D2O
clear signals of only PEG blocks were seen (Figure 3)
which suggests that PVL due to its hydrophobicity
forms the inner core whereas PEG is the exposed
hydrated corona. VEV copolymeric micelles were char-
acterized using particle size analyzer for their size and
polydispersity. As shown in Table 1, copolymer VEV
gave micelles in nanometer range with a low polydisper-
sity. Also the low CMC value for micelle formation sug-
gests that VEV can be a good nanocarrier for drug
delivery.
Preparation and properties of DOX loaded copolymeric
micelles (VEVDMs)
Avoiding the time consuming and low encapsulation effi-
ciency yielding methods like dialysis and nanoprecipitation
[25], we employed a novel single emulsion method for the
preparation of DOX loaded copolymeric micelles using
copolymer VEV. In spite of aqueous solubility of DOX the
Figure 2 Fourier Transform Infra Red spectra.F T - I Rs p e c t r ao f
commercially bought monomers (A) δ-Valerolactone (VL) (B) Poly
(ethylene glycol) (PEG) and the synthesized copolymer VEV (C) Poly
(δ-valerolactone)/Poly(ethylene glycol)/Poly(δ-valerolactone) (VEV)
copolymer were recorded using potassium bromide pellets.
Figure 3
1H Nuclear Magnetic Resonance spectra.
1HN M R
spectra of commercially bought monomers (A) δ-Valerolactone (VL)
(B) Poly(ethylene glycol) (PEG) and the synthesized copolymer VEV
(C) Poly(δ-valerolactone)/Poly(ethylene glycol)/Poly(δ-valerolactone)
(VEV) copolymer were recorded in CDCl3 and D2O as solvents.
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size range of 90 nm (Figure 6) with high drug entrapment
efficiency and yield (Table 2).
Stability studies of VEVDMs showed that there was no
significant change in micelle mean size and polydispersity
index upon storage at 4°C for a period of one year (data
no shown). Also, VEVDMs were easily redispersible in
water which is very important for their application in drug
delivery. The drug release profile from DOX loaded
micelles showed that VEVDMs were able to sustain DOX
release for more than two weeks with dependence on the
pH of the release media (Figure 7). VEVDMs at pH 7.4
released only 15% DOX in the first hour whereas almost
double amount of DOX was released at pH 5 during the
same time. At pH 5, almost 100% DOX was released in
two weeks but at pH 7.4 more than 15% of drug remained
entrapped. However, free DOX at pH 7.4 and 5, diffused
quickly through the dialysis membrane with almost 90%
release with in 24 h. These results indicate that DOX
release from VEVDMs is controlled and pH dependent.
VEVDMs showed enhanced cellular uptake
To analyze the cell uptake of VEVDMs by MCF7 and
U87MG cells, intracellular fluorescence of DOX was eval-
uated using CLSM and the fluorescence intensity of
micelles was compared to free DOX using FACS. Confocal
images showed better intensity of fluorescence in both the
cell lines when incubated with VEVDMs in comparison to
its free state. For a quantitative analysis of intracellular
uptake, the fluorescence intensity in cells incubated with
Figure 4 Molecular weight distribution. The molecular weight of
the synthesized VEV copolymer was determined using gel
permeation chromatography (GPC) on a liquid chromatography
system using tetrahydrofuran (THF) as the eluent.
Figure 5 Thermal analysis of VEV copolymer.( A )D i f f e r e n t i a l
thermal analysis (DTA) and (B) Thermogravimetric analysis (TGA) of
VEV copolymer were recorded under nitrogen flow at a scanning
rate of 10°C min
-1.
Table 1 Characterization of VEV micelles
Polymer Micelle size (nm) PDI
a CMC
b (mg/L)
VEV 83 ± 2.5 0.17 ± 0.008 1.16 ± 0.03
aPolydispersity
bCritical micelle concentration
Figure 6 Transmission Electron Microscope image of
doxorubicin loaded VEV micelles (VEVDMs). For TEM, the sample
of VEVDMs suspension in water milli-Q was dropped onto formvar-
coated grids without being negatively stained. Measurements were
taken only after the sample was completely dried.
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is worth noting here that the intensity of MCF7 cells and
U87MG cells incubated with VEVDMs showed almost 2-3
f o l d si n c r e a s ei nc e l l u l a ru p t a k ei nc o m p a r i s o nt of r e e
DOX (Figure 8).
Micellar DOX of non-toxic VEV copolymer exhibited
better in vitro cytotoxicity with smaller IC50 values
Before analyzing VEV micelles as carriers for drug deliv-
e r yw ec h e c k e di t sc y t o t o x i c i t yi nM C F 7a n dU 8 7 M G
cell lines. The cells were exposed to varying concentra-
tions of VEV ranging from 0.001 mg/ml to 0.1 mg/ml
for 24, 48 and 72 h and checked for cytotoxicity. VEV
triblock copolymeric micelles showed no cytotoxicity to
highest copolymer concentration (0.1 mg/ml) tested
even after 72 h incubation (Figure 9). This suggests that
neither VEV nor its hydrolysis products are toxic show-
ing the ability of VEV to be used as a carrier for drug
delivery.
The cytotoxicity of free DOX and VEVDMs with
increasing concentrations of 0.01-100 μM was evaluated
in both the cell lines for 24, 48 and 72 h using MTT
assay. VEVDMs exhibited enhanced cytotoxicity to both
the cells when compared to pristine DOX in a dose and
time dependent manner (Figure 10). The IC50 values
calculated from dose responsive curve summarized in
Table 3 showed that VEVDMs gave much lower IC50
values than pristine DOX at all the time durations
showing that micellar DOX was more potent in killing
cancer cells.
Annexin V-FITC showed enhanced apoptosis by VEVDMs
To measure and compare the extent of apoptosis
induced by 1 μM of free DOX and VEVDMs on incuba-
tion for 24 h, FITC-conjugated annexin staining was
done and analyzed using flow cytometer. Annexin stain-
ing which identifies cell surface changes that occur in
the early stages of apoptosis show a right shift in the
FACS histogram due to fluorescence emitted by apopto-
tic cells. The histogram of VEVDMs treated cells on
annexin staining suggested that 45.7 and 19.5% MCF7
and U87MG cells underwent apoptosis, whereas only
34.9 and 9.1%, MCF7 and U87MG cells were apoptotic
after treatment with equivalent concentration of free
DOX. Also, empty VEV micelles showed no annexin
Table 2 Characterization of doxorubicin loaded VEV
micelles (VEVDMs)
Sample Encapsulation
efficiency%
Diameter
(nm)
Yield% Polydispersity
VEVDMs 56.2 ± 2.4 90.4 ± 3.5 80.9 ±
4.0
0.173 ± 0.01
Figure 7 In vitro release of doxorubicin from micelles. Release pattern of free doxorubicin in comparison to DOX entrapped in VEV micelles
in phosphate buffer at pH 7.4 and pH 5.0, and 37°C. All the measurements were done in triplicate. The results are expressed as arithmetic mean
± standard error on the mean (S.E.M).
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biocompatibility (Figure 11).
Better PARP cleavage induced by VEVDMs
To detect the cleavage of PARP, a DNA repairing pro-
tein and hallmark of apoptosis, western blot was done.
Immunoblot analysis showed that the intensity of the
116-kDa PARP decreased considerably in both the cell
lines on incubation with DOX micelles in comparison
to the groups treated with the same concentration of
free DOX (Figure 12). Since PARP cleavage is a clear
indicator of apoptosis, these results show the efficiency
of VEVDMs to cause cell death.
Induction of cell cycle arrest by low concentrations of
VEVDMs
Since same concentration of DOX micelles showed bet-
ter results of cytotoxicity and apoptosis, we analyzed the
influence of VEVDMs on cell cycle at a concentration
half that of free DOX using flow cytometer. As DOX is
known to induce G2/M phase arrest, the cells treated
with DOX formulations showed a clear G2/M arrest.
However, it is important to note that both MCF7 and
U 8 7 M Gc e l l s( F i g u r e1 3 )s h o w e dac o m p a r a b l eG 2 / M
phase arrest accompanied by a significant S phase arrest
with VEVDMs even at concentration half that of free
drug which clearly indicates their superior activity.
Discussion
Polymeric micelles using triblock copolymers have been
widely studied for drug delivery due to their properties
that include thermodynamic stability, increased bioavail-
ability, enhanced solubilization of poorly soluble drugs
and targeting ability [5]. Although, numbers of copoly-
mers based on PEG have been already reported, the real
potential of δ-valerolactone based triblock copolymer is
poorly addressed. In the present study we report the
synthesis, characterization and in vitro antitumor evalua-
tion of δ-valerolactone and PEG based triblock copoly-
m e r i cm i c e l l e sf o rt h ed e l i v e r yo fa n t i c a n c e ra g e n t ,
doxorubicin. Effective ring opening polymerization using
stannous octoate was carried out using δ-valerolactone
with PEG having molecular weight of 2000 (Figure 1).
Confirmation of the synthesis of new copolymer poly(δ-
valerolactone)/poly(ethylene glycol)/poly(δ-valerolactone)
(VEV) was done using IR (Figure 2) and NMR (Figure 3).
In agreement with the previous reports, good polymeriza-
tion efficiency with low PDI values (Figure 4) was
obtained with the selected low molecular weight of PEG,
PEG2000 [31]. One of the major reasons behind studying
δ-valerolactone based micelles for drug delivery was that
the thermodynamic as well as kinetic stability of micelles
is expected to increase with the increase in the hydropho-
bicity and state of the micelle core [31]. VEV showed
good thermal stability (Figure 5) which is in agreement
Figure 8 Sub-cellular internalization of DOX entrapped VEV micelles (VEVDMs). MCF7 and U87MG cells were treated with 1 μMD O X
formulations. Micelle uptake of VEVDMs by MCF7 and U87MG cells in comparison to free DOX after 2 h of incubation at 37°C is shown by (A)
CLSM images showing the internal fluorescence of DOX in cells at a magnification of 60× (B) Comparison of fluorescence intensity by flow
cytometry to analyze the extent of internalization.
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Page 6 of 14Figure 9 Cytotoxicity study of VEV copolymer. The biocompatibility analysis of empty VEV micelles on MCF7 and U87MG cells at 24, 48 and
72 h on incubation with the concentrations as indicated was analyzed using MTT assay. All the measurements were done in six replicates. The
results are expressed as arithmetic mean ± standard error on the mean (S.E.M).
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Page 7 of 14Figure 10 Cell viability assay. Comparison of the cell viabilities of MCF7 and U87MG cells on treatment with free DOX and equivalent
concentrations of VEVDMs as indicated on 24, 48 and 72 h incubation was done by MTT. All the measurements were done in six replicates and
the results are expressed as arithmetic mean ± standard error on the mean (S.E.M) with statistical significance *p < 0.05, **p < 0.01.
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high hydrophobic nature of δ-valerolactone. VEV formed
stable micelles (Table 1) having inner PVL core and
outer PEG blocks (Figure 14) as explained from NMR
studies and is because of its amphiphilic nature [30].
These micelles were further assessed for biological
evaluation of VEV as a carrier using doxorubicin (DOX)
as the model drug.
The modified single emulsion solvent evaporation
method adopted for the preparation of DOX loaded
Table 3 IC50 values (in equivalent μM DOX) of MCF7 and
U87MG cells cultured with VEVDMs vs. free doxorubicin
in 24, 48, 72 h
Incubation time
(h)
IC50 MCF7 cells (μM) IC50 U87MG cells (μM)
Free
DOX
DOX
micelles
Free
DOX
DOX
micelles
24 25.8 5.73 31.21 18.471
48 8.239 2.369 4.149 1.138
72 0.05 0.0091 0.7255 0.1517
Figure 11 Apoptosis analysis by FACS using Annexin V-FITC stain assay. MCF7 and U87MG cells were incubated with 1 μMo fD O X
formulations for 24 h. To compare apoptosis, FITC-conjugated annexin binding to phosphatidyl serine, exposed to the outer leaflet, on
treatment with DOX formulations was measured by FACS.
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and efficient for the fabrication of drug entrapped
micelles but also gave particles in the size range of 90
nm (Figure 6) with high encapsulation efficiency and
yield (Table 2). Here, the particle size is a very impor-
tant physical parameter because it directly affects the
cellular uptake capability. The analysis of DOX release
from micelles showed a biphasic pattern with first phase
of slight burst release followed by second phase of
sustained release continuing over a period of two weeks
(Figure 7). The drug release from micelles showed pH
dependence which might be due to the variation in the
hydrolysis of ester chain and DOX solubility with chan-
ging pH [33,34]. This slow and sustained release from
VEVDMs could be more desirable for the delivery of
DOX to solid tumors in vivo. Although, actual applica-
tion need the evaluation of these micelles in animal
models, sustained drug release from VEVDMs supports
the idea of using VEV copolymer based micelles for
controlled delivery of anticancer agents.
Enhanced intracellular uptake of VEVDMs by MCF7
and U87MG cells as shown by confocal images and FACS
(Figure 8) may be attributed to the small size of drug
loaded micelles with PEG on their surface. Since few stu-
dies have reported that based on biocompatibility ε-capro-
lactone based copolymers are better for drug delivery
applications in comparison to δ-valerolactone [15,17], we
analyzed the cytotoxicity of VEV and found that the copo-
lymer showed no cytotoxicity at concentrations up to
0.1 mg/ml even on incubation of 3 days (Figure 9). Since
lesser concentrations of drug loaded micelles are for
administration, no issues of biocompatibility are expected.
Moreover, after dilution with large volume of body fluid in
vivo, 0.1 mg/ml represents a much higher intravenous
material dose than required for in vivo drug delivery.
Therefore, VEV can be considered to be non toxic and
biocompatible. However, intracellular toxicity evaluation
of VEVDMs induced higher cell killing in both cells in a
concentration and time dependent manner (Figure 10).
Considerable lower IC50 values of VEVDMs (Table 3)
might be due to the enhanced cellular uptake accompa-
nied by a slight burst release which showed acceleration in
Figure 12 PARP cleavage determination by western blot
analysis. Comparison of PARP cleavage induced by 3 μMo f
VEVDMs to free DOX in MCF7 and U87MG cells on 24 h incubation.
Immunoblotting was carried out using antibodies specific for PARP
and detected using enhanced chemiluminescence method.
Figure 13 Cell cycle arrest analysis by FACS. Effect of 0.05 μM VEVDMs treatment on cell cycle of MCF7 and U87MG cell lines in comparison
to a double concentration of 0.1 μM free DOX on 24 h incubation was assessed by FACS.
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FITC fluorescence (Figure 11) and intensity of cleaved
PARP (Figure 12) which are clear indicators of apoptosis
as reported in our earlier studies [35], confirms that
VEVDMs are more effective in inducing cell death. In
agreement with previous reports of DOX induced DNA
damage occurring predominantly in the G2/M phase of
cell cycle [36], VEVDMs even at half the concentration of
free DOX induced comparable G2/M arrest accompanied
by a higher S phase arrest (Figure 13). Since cell cycle
arrest is doxorubicin concentration and exposure time
dependent with higher concentrations inducing delayed S
phase transit [37,38], higher S phase arrest by half dose of
VEVDMs may serve the same purpose as done by a dou-
ble amount of free DOX. Thus, the higher apoptosis
induced by VEVDMs might also be attributed to the fate
of cell cycle arrest. Another very important thing to be
noted is that VEVDMs showed better antitumor activity
against both the cell lines irrespective of their nature [39],
which suggests their use against a variety of tumors.
Hence, our study clearly indicates the challenging
potential of VEVDMs for cancer treatment with
enhanced micellar stability imparted by the high hydro-
phobic nature of δ-valerolactone. The superior antitu-
mor efficacy may be accounted on the basis of higher
cellular uptake, DOX releasei na c i d i cc o n d i t i o n sa n d
cell cycle arrest. Although, further evaluation of
VEVDMs in vivo model is required, these PEGylated
micelles certainly possess the tendency to accumulate in
solid tumors with increased bioavailability [40,41] to
deliver the anticancer agent for a long-lasting tumor
containment.
Conclusions
An o v e lδ-valerolactone and PEG based triblock copolymer
was synthesized and characterized for drug delivery appli-
cations. VEV prepared by ring opening polymerization
showed good micelle formation tendency and no cellular
toxicity. To evaluate VEV as a carrier, DOX was
successfully loaded in VEV using a modified single emul-
sion method with high encapsulation efficiency and yield.
DOX release from VEVDMs continued for more than two
weeks and was found to be pH dependent. VEVDMs
obtained in the size range of 90 nm showed enhanced cel-
lular uptake efficiency and much lower IC50 values in com-
parison to pristine DOX. Moreover, the efficiency of DOX
micelles to induce apoptosis accompanied by significant
cell cycle arrest supports the idea of using VEVDMs
against malignancy. Although additional studies are
required to evaluate the in vivo behavior of VEV, our
results confirm the potential of VEVDMs in chemotherapy
and VEV as a carrier for future applications in drug
delivery.
Methods
Materials
δ-valerolactone (VL), doxorubicin hydrochloride (DOX),
stannous octoate, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT), Pluronic F-68,
Ribonuclease A, 1,6-diphenyl-1,3,5-hexatriene (DPH) and
Annexin V apoptosis detection kit were purchased from
Sigma-Aldrich, Steinheim, Germany. Polyethylene Glycol
2000 (PEG) was obtained from Merck Schuchardt OHG,
Germany. Poly (ADP-ribose) polymerase (PARP) was
bought from cell signaling and enhanced chemilumines-
cence kit from GE Amersham. Human breast adenocarci-
noma (MCF7) and glioblastoma (U87MG) cells were
provided from ATCC (USA) and maintained in DMEM
medium containing 10% fetal bovine serum (Sigma,
USA) and 1% antibiotic antimycotic cocktail (Himedia,
India). All solvents were of analytical grade.
Synthesis of poly (δ-valerolactone)/poly (ethylene glycol)/
poly (δ-valerolactone) (VEV) copolymer
The triblock copolymer, VEV was synthesized by ring
opening polymerization of PEG and VL in the presence
of stannous octoate as catalyst as reported [30], with
some modifications. In a typical procedure, PEG and VL
Figure 14 Schematic illustration to represent the structure of VEVDMs. Schematic diagram showing the structure of micelles formed on
DOX entrapment in VEV copolymeric micelles. The micelle is represented by a hydrophobic PVL core and hydrophilic PEG on the surface with
the drug entrapped inside the hydrophobic matrix.
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ate (0.005 mol %) were added to the reaction vessel and
placed under nitrogen in an oil bath at 110°C with mag-
netic stirring for 24 h. The resulting mixture was cooled
to room temperature, dissolved in dichloromethane and
precipitated in an excess amount of cold ether to
remove residual monomers. Purification of the copoly-
mer was achieved by the dissolution/precipitation
method with dichloromethane and ether, followed by fil-
tration and drying in vacuum.
Characterization of VEV copolymer
To characterize VEV, Fourier transform infrared (FT-IR)
spectra were measured by FT-IR spectrometer (Nicolet
5700) using potassium bromide (KBr) pellets. Proton
nuclear magnetic resonance
1H spectra (NMR) were
obtained using Bruker 500 MHz with deuterated chloro-
form (CDCl3) or water (D2O) as solvent. To analyze the
molecular weight, gel permeation chromatography (GPC)
measurements were carried out on a Waters 515 liquid
chromatography system equipped with two Waters Styra-
gel HR 5ETHF columns and a Waters 2414 refractive
index detector using tetrahydrofuran (THF) as the eluent
(1.0 ml/min). In addition, thermal stability of the polymer
was measured by differential thermal analysis (DTA) and
thermogravimetric analysis (TGA) using SDT-2960, TA
Instruments Inc under nitrogen flow at a scanning rate of
10°C min
-1.
Micellization and characterization
VEV polymeric micelles were prepared by a known precipi-
tation method [42]. Briefly, 100 mg of polymer dissolved in
10 ml of acetone was added to 50 ml aqueous media and
stirred overnight at room temperature to remove the
organic solvent. The polymeric micelles were then lyophi-
lized and resuspended before every analysis. The size of
micelles was measured using a particle size analyzer (Beck-
man Coulter Delsa Nano Particle Analyzer). The critical
micelle concentration (CMC) of VEV micelles was deter-
mined by fluorescence based method using DPH as a probe
[30]. In brief, VEV aqueous solutions were added to DPH
solution (0.4 mM), such that the final concentration of
copolymer ranged from 0.001-1 wt%. The samples were
equilibrated overnight at room temperature and UV
absorption was recorded at 365 nm on a UV-VIS spectro-
photometer (Perkin Elmer, USA). The critical micelle con-
centration (CMC) was calculated on the basis of absorption
vs. logarithmic polymer concentrations. Micelles were also
analyzed by
1H NMR using deuterated water as a solvent.
Preparation and characterization of DOX loaded VEV
micelles (VEVDMs)
In a novel method for preparing drug entrapped
micelles using a triblock copolymer, single emulsion
solvent evaporation method was adopted. Briefly,
DOX (1:100 w/w) dissolved in methanol (1:10 v/v)
was added to VEV solution in acetone to form the
organic phase, which on addition to an aqueous phase
containing Pluronic F-68 (1%) gave emulsion contain-
ing micelles. This emulsion after sonication was sub-
jected to overnight stirring at room temperature to
get micellar suspension. VEVDMs in dry powder form
were obtained after centrifugation followed by
lyophilization.
Size analysis of VEVDMs was done using particle size
analyzer (Beckman Coulter Delsa Nano Particle Analy-
zer) and images were taken using a transmission electron
microscope (TEM, JEOL 1011, Japan). To calculate the
drug content in micelles, weighed amount of dried drug
loaded micelles were dissolved in DMSO (dimethyl
sulphoxide) and the drug amount was calculated accord-
ing to a standard curve obtained using DMSO solutions
of known concentrations of free DOX by UV spectro-
photometer (Perkin Elmer, USA) at the detection wave-
length 480 nm. The encapsulation efficiency was
expressed as the ratio of DOX in micelles to the initial
amount of drug used. The yield corresponds to the ratio
of amount of micelles recovered to the total amount of
polymer and drug used in formulation.
In vitro drug release
DOX loaded micelles were dispersed in distilled water (1
mg/ml) and then placed in a dialysis bag (MW cut off:
3500). The dialysis bag was then immersed in 15 ml of
buffer solutions with pH 5.0 (acidic) and 7.4 (physiologi-
cal) and incubated at 37°C. At specific time intervals,
the drug released solution was replaced with equal
amount of fresh media and the amount of DOX released
was analyzed using UV-vis spectrophotometer at 480
nm. The release kinetics at two different was compared
to that of free DOX.
Cellular uptake studies
To visualize the cellular uptake of drug-loaded micelles,
cells were grown on cover slips placed in 24 well plates.
After 24 hours cells were treated with 1 μM DOX formu-
lations and incubated for 2 h. The cells were washed,
mounted and examined under a confocal laser scanning
microscope (CLSM, Leica DMI 4000B) at a magnification
of 60× for intracellular DOX fluorescence. Furthermore,
the intensity of DOX fluorescence on cellular uptake was
analyzed using flow cytometry (FACS Aria, BD, USA).
Cells seeded in six-well culture plates (5 × 10
4) after 24 h
incubation, were treated with 1 μMD O Xf o r m u l a t i o n s .
After exposure of 2 h, the cells were washed with cold
PBS three times, harvested using trypsin-EDTA and ana-
lyzed for internal fluorescence of DOX using flow
cytometer.
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To assess the cytotoxicity of empty VEV micelles, free
DOX and VEVDMs, 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction assay
was performed [35]. Briefly, human breast adenocarci-
noma (MCF7) and gliomablastoma (U87MG) cells were
seeded (5.0 × 10
3/well) and incubated for 24 h in 96-
well plates. Cells were incubated with various concentra-
tions of VEV, free DOX and VEVDMs as indicated and
incubated for 24, 48 and 72 h, respectively. Following
treatment the amount of formazan crystals formed was
measured after 4 h of MTT addition (10% v/v) by add-
ing isopropyl alcohol and OD measurement at 570 nm.
The relative cell viability in percentage was calculated as
(Atest/Acontrol) × 100.
Annexin V-FITC staining
To examine cell apoptosis induced by DOX formula-
tions, Annexin V-FITC stain assay was performed on
both the cell lines [35]. Briefly, cells cultured with or
without drug (1 μM) for 24 h were washed in cold PBS
and resuspended in binding buffer. Afterwards, cells
were stained with FITC-labeled annexin using Annexin
V-FITC Apoptosis Detection Kit according to the manu-
facturer’s instructions and a flow cytometric analysis was
then carried out using FACS Aria (Special order system,
BD, USA).
Western blot analysis
2×1 0
6 cells were seeded in 100-mm culture plates and
treatments containing 3 μMD O Xw a sg i v e nf o r2 4h .
Cells were then lysed and the total protein content was
measured using Bradford’sr e a g e n t .5 0μg of total pro-
tein was loaded for SDS-PAGE. Immunoblotting was
carried out using antibodies specific for PARP and
detected using enhanced chemiluminescence (ECL)
method [35].
Cell cycle analysis
For flow cytometric analysis, 10
6 cells were seeded in six-
well culture dishes and given treatment of 0.05 μM
VEVDMs and 0.1 μM free DOX for 24 h. Cells were har-
vested and fixed with 70% ethanol for 1 h. The fixed cells
were then given RNAse A (100 mg/ml) treatment for 1 h
at 37°C followed by propidium iodide (10 mg/ml) incuba-
tion for 15 min. Finally, cells were analyzed using FACS
Aria (Special order system, BD, USA) [35].
Statistics
All the measurements were done in three or more repli-
cates. The results are expressed as arithmetic mean ±
standard error on the mean (S.E.M). For cytotoxicity
experiments the normalization of the data was done by
considering the mean value of the untreated samples as
100%. All other data points were expressed as percentage
of the control. Statistical difference (*p < 0.05, **p < 0.01)
were calculated using GraphPad Instat 3.
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